News
VTRS
16.13
+1.13%
0.18
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
Reuters · 1d ago
Viatris Inc. Stock Rallies 6.7%, Outperforms Market
Dow Jones · 2d ago
Viatris Inc. stock rises Monday, outperforms market
MarketWatch · 2d ago
Viatris gains as UBS upgrades to Buy on outlook and pipeline
Seeking Alpha · 2d ago
VIATRIS INC <VTRS.O>: UBS RAISES TARGET PRICE TO $18 FROM $11
Reuters · 2d ago
Stocks Settle Higher on Strength in Tech
Barchart · 2d ago
Why Viatris (VTRS) Stock Is Up Today
Barchart · 2d ago
Viatris upgraded to Buy from Neutral at UBS
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)
TipRanks · 2d ago
Weekly Report: what happened at VTRS last week (0202-0206)?
Weekly Report · 2d ago
Women Are One Patch Away From Menopause Relief -- If Only They Could Find It
The Wall Street Journal · 5d ago
Large-cap stocks with lowest dividend growth grade
Seeking Alpha · 5d ago
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)?
Simply Wall St · 5d ago
Is It Time To Reassess Viatris (VTRS) After Its Recent Share Price Strength
Simply Wall St · 02/05 00:42
Hikma Pharmaceuticals gains amid takeover speculation
Seeking Alpha · 02/04 16:47
Viatris Announces Chief Legal Officer Transition and Successor
TipRanks · 02/03 22:18
Viatris Inc. publishes update to financial calendar
Reuters · 02/03 21:34
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
PR Newswire · 02/03 21:34
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.